Laboratory Co. of America Holdings (NYSE:LH) Shares Sold by Eukles Asset Management

Eukles Asset Management decreased its position in shares of Laboratory Co. of America Holdings (NYSE:LH) by 5.3% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 16,877 shares of the medical research company’s stock after selling 947 shares during the quarter. Laboratory Co. of America comprises 1.6% of Eukles Asset Management’s holdings, making the stock its 18th biggest position. Eukles Asset Management’s holdings in Laboratory Co. of America were worth $3,870,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SouthState Corp purchased a new position in shares of Laboratory Co. of America in the 3rd quarter valued at approximately $28,000. Horizon Bancorp Inc. IN purchased a new position in Laboratory Co. of America in the 3rd quarter valued at $29,000. Fortitude Family Office LLC increased its stake in Laboratory Co. of America by 312.5% in the 4th quarter. Fortitude Family Office LLC now owns 132 shares of the medical research company’s stock valued at $30,000 after buying an additional 100 shares during the period. Geneos Wealth Management Inc. raised its position in Laboratory Co. of America by 309.8% during the 4th quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company’s stock worth $39,000 after buying an additional 127 shares during the last quarter. Finally, Riverview Trust Co lifted its stake in shares of Laboratory Co. of America by 172.6% in the 3rd quarter. Riverview Trust Co now owns 169 shares of the medical research company’s stock worth $38,000 after acquiring an additional 107 shares during the period. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Insider Activity at Laboratory Co. of America

In other Laboratory Co. of America news, Director Kerrii B. Anderson sold 1,000 shares of Laboratory Co. of America stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $235,000.00. Following the completion of the sale, the director now directly owns 12,722 shares of the company’s stock, valued at approximately $2,989,670. The trade was a 7.29 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Amy B. Summy sold 3,672 shares of the stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $238.91, for a total value of $877,277.52. Following the transaction, the chief marketing officer now directly owns 4,318 shares in the company, valued at approximately $1,031,613.38. This represents a 45.96 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 18,383 shares of company stock valued at $4,408,373. 0.85% of the stock is owned by insiders.

Laboratory Co. of America Stock Performance

Shares of LH opened at $246.18 on Monday. Laboratory Co. of America Holdings has a 12-month low of $191.97 and a 12-month high of $258.59. The stock has a market cap of $20.59 billion, a P/E ratio of 27.91, a PEG ratio of 1.84 and a beta of 1.07. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.67. The company has a 50-day moving average of $236.67 and a two-hundred day moving average of $229.85.

Laboratory Co. of America (NYSE:LH) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. As a group, research analysts predict that Laboratory Co. of America Holdings will post 15.96 EPS for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Investors of record on Thursday, February 27th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.17%. The ex-dividend date is Thursday, February 27th. Laboratory Co. of America’s dividend payout ratio is presently 32.65%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on LH shares. Barclays dropped their price target on shares of Laboratory Co. of America from $271.00 to $260.00 and set an “equal weight” rating on the stock in a research note on Friday. Jefferies Financial Group boosted their target price on Laboratory Co. of America from $275.00 to $290.00 and gave the stock a “buy” rating in a research report on Thursday. StockNews.com raised Laboratory Co. of America from a “hold” rating to a “buy” rating in a report on Friday. Bank of America upped their price objective on Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Finally, Piper Sandler raised their target price on Laboratory Co. of America from $235.00 to $240.00 and gave the company a “neutral” rating in a report on Monday, October 28th. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $263.77.

Laboratory Co. of America Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.